Tuberculosis remains one of the leading causes of death from infectious diseases worldwide, and its effective treatment requires prolonged multidrug regimens. Hypersensitivity reactions to antituberculosis drugs (ATDs) can significantly compromise treatment outcomes. These reactions range from mild skin eruptions to severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms. The most frequently implicated agents are pyrazinamide, rifampin, isoniazid, and ethambutol, which are often associated with multiple drug hypersensitivity.Diagnostic tools such as patch testing, intradermal testing, and lymphocyte transformation tests may aid in identifying the culprit drug, but their sensitivity and specificity are limited. In cases of SCARs, immediate discontinuation of the offending agent is essential, and systemic corticosteroids may be effective in moderate to severe cases. Reintroduction of ATDs may be attempted through drug rechallenge or desensitization. Although drug reintroduction was traditionally contraindicated in patients with SCARs, recent reports have demonstrated successful desensitization when performed cautiously with informed consent. Breakthrough reactions may occur during desensitization, but they are often manageable with dose or interval adjustments. The development of standardized desensitization protocols for ATD-induced hypersensitivity remains an important future objective. In addition, ATDs can also induce classical immediate-type reactions such as urticaria and angioedema. In rare cases, they may present as atypical non-IgE-mediated anaphylaxis, for which no definitive diagnostic tools are currently available. Severe reactions may occur upon re-administration and cannot be prevented by desensitization. Thus, careful differential diagnosis is essential and any form of re-exposure is strictly contraindicated.

Leptomeningeal myelomatosis represents an uncommon but clinically consequential form of extramedullary disease. Because its manifestations frequently overlap with vascular and infectious conditions, timely recognition is challenging. In particular, isolated speech disturbance without accompanying motor deficits can be misattributed to acute ischemic stroke or focal seizures, potentially delaying appropriate therapy. Here, we report a case of 81-year-old female patients presenting with global aphasia. In this case, brain magnetic resonance imaging and cerebrospinal fluid study including cytology demonstrated leptomeningeal involvement by multiple myeloma.

Purpose: Since 1995, the Korean Gastric Cancer Association (KGCA) has been periodically conducting nationwide surveys on patients with surgically treated gastric cancer. This study details the results of the survey conducted in 2023. Materials and Methods: The survey was conducted from March to December 2024 using a standardized case report form. Data were collected on 86 items, including patient demographics, tumor characteristics, surgical procedures, and surgical outcomes. The results of the 2023 survey were compared with those of previous surveys. Results: Data from 12,751 cases were collected from 66 institutions. The mean patient age was 64.6 years, and the proportion of patients aged ≥71 years increased from 9.1% in 1995 to 31.7% in 2023. The proportion of upper-third tumors slightly decreased to 16.8% compared to 20.9% in 2019. Early gastric cancer accounted for 63.1% of cases in 2023.Regarding operative procedures, a totally laparoscopic approach was most frequently applied (63.2%) in 2023, while robotic gastrectomy steadily increased to 9.5% from 2.1% in 2014.The most common anastomotic method was the Billroth II procedure (48.8%) after distal gastrectomy and double-tract reconstruction (51.9%) after proximal gastrectomy in 2023.However, the proportion of esophago-gastrostomy with anti-reflux procedures increased to 30.9%. The rates of post-operative mortality and overall complications were 1.0% and 15.3%, respectively. Conclusions The results of the 2023 nationwide survey demonstrate the current status of gastric cancer treatment in Korea. This information will provide a basis for future gastric cancer research.

Purpose: Since 1995, the Korean Gastric Cancer Association (KGCA) has been periodically conducting nationwide surveys on patients with surgically treated gastric cancer. This study details the results of the survey conducted in 2023. Materials and Methods: The survey was conducted from March to December 2024 using a standardized case report form. Data were collected on 86 items, including patient demographics, tumor characteristics, surgical procedures, and surgical outcomes. The results of the 2023 survey were compared with those of previous surveys. Results: Data from 12,751 cases were collected from 66 institutions. The mean patient age was 64.6 years, and the proportion of patients aged ≥71 years increased from 9.1% in 1995 to 31.7% in 2023. The proportion of upper-third tumors slightly decreased to 16.8% compared to 20.9% in 2019. Early gastric cancer accounted for 63.1% of cases in 2023.Regarding operative procedures, a totally laparoscopic approach was most frequently applied (63.2%) in 2023, while robotic gastrectomy steadily increased to 9.5% from 2.1% in 2014.The most common anastomotic method was the Billroth II procedure (48.8%) after distal gastrectomy and double-tract reconstruction (51.9%) after proximal gastrectomy in 2023.However, the proportion of esophago-gastrostomy with anti-reflux procedures increased to 30.9%. The rates of post-operative mortality and overall complications were 1.0% and 15.3%, respectively. Conclusions The results of the 2023 nationwide survey demonstrate the current status of gastric cancer treatment in Korea. This information will provide a basis for future gastric cancer research.

Purpose: Since 1995, the Korean Gastric Cancer Association (KGCA) has been periodically conducting nationwide surveys on patients with surgically treated gastric cancer. This study details the results of the survey conducted in 2023. Materials and Methods: The survey was conducted from March to December 2024 using a standardized case report form. Data were collected on 86 items, including patient demographics, tumor characteristics, surgical procedures, and surgical outcomes. The results of the 2023 survey were compared with those of previous surveys. Results: Data from 12,751 cases were collected from 66 institutions. The mean patient age was 64.6 years, and the proportion of patients aged ≥71 years increased from 9.1% in 1995 to 31.7% in 2023. The proportion of upper-third tumors slightly decreased to 16.8% compared to 20.9% in 2019. Early gastric cancer accounted for 63.1% of cases in 2023.Regarding operative procedures, a totally laparoscopic approach was most frequently applied (63.2%) in 2023, while robotic gastrectomy steadily increased to 9.5% from 2.1% in 2014.The most common anastomotic method was the Billroth II procedure (48.8%) after distal gastrectomy and double-tract reconstruction (51.9%) after proximal gastrectomy in 2023.However, the proportion of esophago-gastrostomy with anti-reflux procedures increased to 30.9%. The rates of post-operative mortality and overall complications were 1.0% and 15.3%, respectively. Conclusions The results of the 2023 nationwide survey demonstrate the current status of gastric cancer treatment in Korea. This information will provide a basis for future gastric cancer research.

Background: There is a growing demand for extending dosing intervals of dupilumab injections in patients with atopic dermatitis (AD) due to treatment burden and side effects. However, studies on successful dose reduction in real-world settings are lacking. Objective: To assess the efficacy of a patient-centered dupilumab tapering regimen and to propose guidelines for target patients, appropriate intervals, and timing for tapering. Methods: This single-center retrospective study included moderate to severe adult AD patients who underwent at least 16 weeks of dupilumab treatment. Interval prolongation was considered in controlled patients assessed by Eczema Area and Severity Index (EASI) score and serum inflammatory markers after at least 40 weeks of treatment with a standard regimen. Logistic regression model with generalized estimating equations was used to compare repetitive measurements over time between the two groups. Results: A total of 52 patients were included with 11 patients extending intervals to 3–4 weeks without flare-ups. The mean duration of dupilumab treatment before tapering was 53.27 weeks. The tapering group exhibited significantly lower body mass index. All patients of the tapering group showed EASI scores under 4 and immunoglobulin E (IgE) levels under 1,000 IU/mL at week 40. EASI scores and IgE levels remained consistently low after dose reduction, with a mean follow-up time of 14.36 months. Conclusion Patients with extended dosing intervals demonstrated sustained effectiveness. Dose tapering might be a valuable option for non-obese patients with positive clinical response characterized by an EASI score under 4 and IgE levels under 1,000 at week 40.

BACKGROUND/OBJECTIVES: Colorectal cancer (CRC) is a malignancy that occurs in the colon or rectum and ranks as the second leading cause of cancer-related fatalities globally.Numerous epidemiological studies have revealed a distinct difference in CRC between sexes.Specifically, a lower incidence rate and delayed onset in females than in males. β-Carotene (BC), a provitamin A carotenoid, elicits antioxidant effects; however, the potential sexspecific differences in its anti-colon cancer effect are unknown. This study aims to compare the effect of BC on inflammation between sexes in azoxymethane/dextran sulfate sodium (AOM/DSS)-induced early CRC.MATERIALS/METHODS: The AOM/DSS mouse model was established. In early CRC, systemic changes were assessed using the disease activity index (DAI), serum proinflammatory cytokine levels, estradiol, and retinol concentrations. Local changes were evaluated using colon length, tumor counts, proinflammatory cytokines, and estrogen receptor (ER) α expression in the colon. RESULTS: In early CRC-induced systemic changes, females had higher DAI scores and lower serum estradiol levels than males. DAI scores were decreased in both sexes, however, serum cytokine levels were reduced by BC supplementation only in females. In the early CRC model, the systemic disease activity in females was higher than that in males. Serum retinol concentrations decreased to a greater extent in female AOM/DSS-induced CRC mice than in their male counterparts. In terms of local changes, the colon was shorter and the ERα expression was increased in females. CONCLUSION In early CRC, higher disease activity and specific changes, such as increased DAI scores and reduced serum estradiol in females than in males. BC supplementation could effectively reduce DAI scores and systemic inflammation in both sexes. Notably, serum cytokine levels decreased only in females.